Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. (... Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. (Duet), our majority-owned subsidiary. These programs include three distinctive complementary CpG-STAT3 inhibitors: Antisense ("DUET-101"); RNA silencing ("DUET-202"); and DNA-binding inhibitor ("DUET-301"). The Company may also seek to develop additional drug candidates and identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0003 | 0.0003 | 0.0003 | 1580 | 0.0003 | CS |
4 | -0.0002 | -40 | 0.0005 | 0.0005 | 0.0003 | 36033 | 0.00030066 | CS |
12 | 0 | 0 | 0.0003 | 0.01 | 0.0001 | 20184 | 0.00031395 | CS |
26 | 0.0001 | 50 | 0.0002 | 0.01 | 1.0E-6 | 14289 | 0.00029212 | CS |
52 | -0.0507 | -99.4117647059 | 0.051 | 0.0637 | 1.0E-6 | 10059 | 0.01368221 | CS |
156 | -0.0848 | -99.6474735605 | 0.0851 | 0.156 | 1.0E-6 | 25598 | 0.0738424 | CS |
260 | -0.0848 | -99.6474735605 | 0.0851 | 0.156 | 1.0E-6 | 25598 | 0.0738424 | CS |
銘柄コード | 株価 | 出来高 |
---|---|---|
AITXArtificial Intelligence Technology Solutions Inc (PK) | US$ 0.00275 (0.00%) | 51.06M |
GTEHGenTech Holdings Inc (CE) | US$ 0.000001 (0.00%) | 48.25M |
HMBLHUMBL Inc (PK) | US$ 0.0002 (-33.33%) | 42.65M |
CBGLCannabis Global Inc (PK) | US$ 0.00015 (50.00%) | 41.81M |
GTVHGolden Triangle Ventures Inc (PK) | US$ 0.0008 (33.33%) | 41.61M |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約